Rodriguez et al. [115] investigated the combination of the HDAC inhibitor vorinostat with the PD-1-inhibitor pembrolizumab in patients with PD-L1-positive, immunotherapy-naive R/M HNSCC. This evidence concerns the gene CD274 and head and neck squamous cell carcinoma.